secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001104659-25-100608
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VIRAGE Phase 2b trial meets primary OS endpoint; VCN-01+SoC mOS 10.8 vs 8.6 months
--------------------------------------------------------------------------------

- VCN-01 + gem/nab-paclitaxel met primary OS endpoint in FAS: median 10.8 vs 8.6 months, HR 0.57 (p=0.034).
- PFS improved: 7.0 vs 4.6 months (HR 0.55, p=0.012) and duration of response doubled (11.2 vs 5.4 months).
- Patients receiving 2 VCN-01 doses had greater OS benefit: median 14.8 vs 11.6 months (HR 0.44).
- VCN-01 was safe and well tolerated; related SAEs were transient and resolved.
- Data support further evaluation in larger blinded trial with additional VCN-01 doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925100608/0001104659-25-100608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925100608/tm2529071d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-100608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer